Rubella Diagnostic Testing Market Size (2024 - 2029)

Rubella Diagnostic Testing Market Analysis

The Rubella Diagnostic Testing Market size is estimated at USD 1.39 billion in 2024, and is expected to reach USD 1.79 billion by 2029, growing at a CAGR of 5.23% during the forecast period (2024-2029).

The COVID-19 pandemic significantly impacted the global rubella diagnostic testing market. For instance, an article published in the International Journal of Molecular Epidemiology and Genetics in June 2021 reported that increasing COVID-19 cases kept aside the other diagnostic tests, and thus the rubella diagnostic market witnessed significant challenges during the initial phase of the pandemic. However, in the current scenario, with the decreasing number of COVID-19 cases and the resumption of diagnostic services, the market is expected to witness significant growth over the forecast period.

The factors that are driving the growth of the studied market are government initiatives to curb the rubella virus, increasing incidences of rubella, and the introduction of advanced point-of-care diagnostic technologies. The increasing government initiatives are creating awareness among individuals about the need for rapid rubella diagnostics, thereby driving the market. For instance, in July 2022, the Pradhan Mantri Surakshit Matritva Abhiyan will be launched by the Ministry of Health & Family Welfare (MoHFW), Government of India, with the aim of improving the quality and coverage of antenatal care (ANC), including diagnostics and counseling services, as part of the Reproductive Maternal Neonatal Child and Adolescent Health (RMNCH+A) strategy. It aims to provide assured, comprehensive, and free-of-cost quality antenatal care to all pregnant women on the 9th of every month in their 2nd-3rd trimesters of pregnancy at designated government health facilities. The program covers proper diagnostic testing, including those for rubella, and thus provides better diagnostic services, and such initiatives are driving the growth of the studied market.

The increasing incidence of rubella is also fueling the need for better diagnostics, thereby driving the growth of the studied market. For instance, in March 2022, the World Health Organization (WHO) reported that rubella is a leading vaccine-preventable cause of birth defects. Similarly, an article published in the Rubella Journal of Virology in April 2022 reported that rubella is an acute illness caused by the rubella virus and characterized by fever and rash, with approximately 100,000 congenital rubella syndrome cases occurring per year and being reported globally.

The increasing cases of rubella are increasing the demand for rubella diagnostics and thus driving the growth of the studied market. For instance, an article published by the Multidisciplinary Digital Publishing Institute in October 2022 reported that among the 8082 laboratory-tested specimens from measles and rubella-suspected cases collected at the Department of Virology in Senegal in the year 2021, the serological evidence of rubella infection was 465/6714 (6.9%). Thus, high cases of rubella are increasing the demand for rubella diagnostics and thus fueling the growth of the studied market.

Also, the introduction of point-of-care diagnostics for rubella diagnosis is driving the growth of the studied market. For instance, in an article published in the book Advanced Materials in March 2022, it was reported that recent research efforts have been made to implement fluorescent biosensors into the exploding field of point-of-care testing (POCT), which uses cost-effective strategies for rapid and affordable diagnostic testing for various diseases, including rubella. Thus, the introduction of point-of-care diagnostics is driving the growth of the studied market.

Thus, due to government initiatives to curb the rubella virus, increasing incidences of rubella, and the introduction of advanced point-of-care diagnostic technologies, the market is expected to witness significant growth over the forecast period. However, a lack of awareness among developing regions may slow growth over the course of the study.

Rubella Diagnostic Testing Industry Segmentation

As per the scope of the report, rubella diagnostic testing refers to the detection of the rubella virus. These tests are prescribed for pregnant women and may also be performed on babies born with congenital defects. Rubella can be found with the help of diagnostic tests like latex agglutination, enzyme immunoassay, radioimmunoassay (RIA), and fluorescent immunoassay (FIA), among others.

Testing Technique (Latex Agglutination, Enzyme Immunoassay (EIA), Radioimmunoassay (RIA), Fluorescent Immunoassay (FIA), and Other Testing Techniques), Application (Hospitals, Laboratories, and Other Applications), and Geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America) are the segments of the Rubella Diagnostic Testing Market. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.